Cardiaccs technology is based on a sensor with an accelerometer integrated into a temporary pacemaker lead. The sensor is placed on the heart surface during surgery, measuring the cardiac motion - or contractility - which is a vital parameter for monitoring the cardiac function


Cardiaccs is ISO 13485 certified and quality has been at the centre of everything we do, right from the beginning.

Cardiaccs has established the following Quality Policy:


Our Challenge

Left ventricular failure during heart surgery is mainly caused by myocardial ischemia (insufficient blood flow to the heart muscle) or infarction (death of heart muscle cells), leading to a ten-fold increase in perioperative mortality and morbidity. Many cases of ischemia escape detection because electrocardiography (ECG) and continuous hemodynamic monitoring (such as catheters) are not sensitive enough. Myocardial ischemia is followed by an immediate decrease in myocardial contraction that could be monitored by transesophageal echocardiography. This tool is currently the best for the monitoring of perioperative myocardial ischemia. Unfortunately, there are many limitations with this technique. A skilled operator is needed and only intermittent measurements are available. Thus, there is an urgent need for methods for earlier detection if the treatment of perioperative myocardial ischemia is to improve.

Company History

Cardiaccs was founded in 2009 as a result of 8 years of research and development by the Intervention Centre at Oslo University Hospital in cooperation with Buskerud and Vestfold University College. In 2014, the company was granted funding by the Research Council of Norway through the FORNY2020 programme to commercialise the Cardisense sensor technology.
EACTS Award 2012


The Cardiaccs Team